An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia

NCT00605319

Last updated date
Study Location
New York Hospital, Cornell University
New York, New York, 10065, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Bladder Outlet Obstruction
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40-99 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Male ≥40 years of age

2. Clinical signs and symptoms of frequency and urgency, enlarged prostate and urodynamic study consistent with overactive bladder.

3. IPSS >12, with IPSS QoL > 3 at screening visit.

4. Ability and willingness to correctly complete the micturition diary and all the trial related questionnaires comply with scheduled visits and comply with trial procedures.

5. Capability of understanding and having signed the informed consent form after full discussion of the research, nature of the treatment, and its risks and benefits.

6. Procedure to treat BOO by TURP or PVP greater than or equal to 1 month ago.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. A known history of interstitial cystitis, uninvestigated hematuria, or bladder outlet
obstruction due to: mullerian duct cysts, urethral obstruction due to
stricture/valves/sclerosis of urethral tumor, radiation cystitis, genitourinary
tuberculosis, bladder calculi, or detrusor-sphincter dyssynergia.


2. Evidence of Urinary Tract Infection according to local standard of care.


3. Expectation of initiating treatment during the duration of this study with - any drug
treatment for OAB, any drugs with significant anticholinergic, antispasmodic,
parasympathetic, or cholinergic agonistic effects.


4. Use of any electrostimulation within the 30 days before randomization, or the
expectation to initiate such therapy during the study.


5. Any condition which, in the opinion of the investigator, makes the patient unstable,
or with contraindications for inclusion, e.g., uncontrolled narrow-angled glaucoma,
urinary retention, preplanned prostate surgery, or gastric retention.


6. Significant hepatic or renal disease, defined as twice the upper limit of the
reference ranges regarding serum concentrations of AST, ALT, ALP, urea nitrogen, or
creatinine.


7. Use of any other investigational drug in the 2 months preceding visit 1.


8. History of postural hypotension or syncope in the judgement of the investigator based
on local standards of care.


9. Alcohol and/or any other drug abuse in the opinion of the investigator.


10. Medications such as erythromycin, Biaxin (Clarithromycin), Sporanox (itraconazole),
Nizoral (ketoconazole), Neoral and Sandimmune (cyclosporine), Velban (vinblastine) and
miconazole.


11. Non-medication treatments such as bio-feedback or other bladder training exercises.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Bladder Outlet ObstructionAn Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia
NCT00605319
  1. New York, New York
Male
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia
Official Title  ICMJE An Open Label Study to Measure the Efficacy of Fesoterodine (Toviaz) on Continued Detrusor Overactivity in Patients That Have Undergone Treatment for Bladder Outlet Obstruction
Brief Summary The subjects who have symptoms of overactive bladder (many trips to the bathroom, and urgency with or without the inability to hold your urine until you get to the toilet) are invited to participate in this research study.
Detailed Description

Overactive bladder is a common sequelae of long-term bladder outlet obstruction in men. Unfortunately, it does not often resolve after treatment of the obstruction (transurethral resection of the prostate). These patients are usually started empirically on alpha-blockers or occasionally anticholinergic agents, former used to treat enlarged prostate medically, and latter, to treat overactive bladder. We hypothesize that these patients would be significantly improved with a long-acting anticholinergic agent such as long acting Fesoterodine or Toviaz.

Earlier studies have shown that anticholinergic drugs seem to have a beneficial effect on symptoms of patients with bladder outlet obstruction and overactive bladder. In addition, anticholinergic drug Toviaz is not associated with increased incidence of complication like acute urinary retention, a state where patient is unable to empty the bladder as an adverse effect of the drug.

A large proportion of our patients that are undergoing treatment for bladder outlet obstruction also have overactive bladder. We propose an open label trial to evaluate the efficacy of Toviaz (fesoterodine) 4mg to 8 mg in patients that have continued symptoms of overactive bladder one month following transurethral resection of the prostate. Toviaz is an antimuscarinic and anticholinergic agent, and is a newer formulation of Detrol. Patients with overactive bladder on urodynamic test preoperatively will be considered. If these patients continue to have symptoms at the one-month post-operative visit, they will be enrolled into the study. We expect a total of 25 patients to be enrolled within 4 months. All patients will receive Toviaz 4mg to 8 mg. The patients will be followed at 3 months post-op, 4 months post-op, and 7 months post-op. At each post-op visit, the patients will fill out an AUA symptom score questionnaire, have noninvasive uroflowmetry performed, and have a post-void residual measured by bladder scan. Using standard statistical analysis, we will see if there is a difference in symptoms, post-void residual, or maximum flow rate between baseline and 7 months post-op. We will continue the study to evaluate long-term efficacy, dropout rate, and complications. An FDA approved flexible dosing regimen will be allowed for the duration of the study.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Bladder Outlet Obstruction
Intervention  ICMJE Drug: Toviaz (Fesoterodine)
4mg to 8mg by mouth once daily
Other Name: Toviaz
Study Arms  ICMJE Toviaz (Fesoterodine)
Toviaz 4mg to 8mg
Intervention: Drug: Toviaz (Fesoterodine)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 12, 2018)
17
Original Estimated Enrollment  ICMJE
 (submitted: January 30, 2008)
50
Actual Study Completion Date  ICMJE January 2013
Actual Primary Completion Date January 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Patients will be selected by the investigator and sub-investigator's patient population, and physician referrals. All patients will meet the inclusion/ exclusion criteria.

Inclusion Criteria

  1. Male ?40 years of age
  2. Clinical signs and symptoms of frequency and urgency, enlarged prostate and urodynamic study consistent with overactive bladder.
  3. IPSS >12, with IPSS QoL > 3 at screening visit.
  4. Ability and willingness to correctly complete the micturition diary and all the trial related questionnaires comply with scheduled visits and comply with trial procedures.
  5. Capability of understanding and having signed the informed consent form after full discussion of the research, nature of the treatment, and its risks and benefits.
  6. Procedure to treat BOO by TURP or PVP greater than or equal to 1 month ago.

Exclusion Criteria

  1. A known history of interstitial cystitis, uninvestigated hematuria, or bladder outlet obstruction due to: mullerian duct cysts, urethral obstruction due to stricture/valves/sclerosis of urethral tumor, radiation cystitis, genitourinary tuberculosis, bladder calculi, or detrusor-sphincter dyssynergia.
  2. Evidence of Urinary Tract Infection according to local standard of care.
  3. Expectation of initiating treatment during the duration of this study with - any drug treatment for OAB, any drugs with significant anticholinergic, antispasmodic, parasympathetic, or cholinergic agonistic effects.
  4. Use of any electrostimulation within the 30 days before randomization, or the expectation to initiate such therapy during the study.
  5. Any condition which, in the opinion of the investigator, makes the patient unstable, or with contraindications for inclusion, e.g., uncontrolled narrow-angled glaucoma, urinary retention, preplanned prostate surgery, or gastric retention.
  6. Significant hepatic or renal disease, defined as twice the upper limit of the reference ranges regarding serum concentrations of AST, ALT, ALP, urea nitrogen, or creatinine.
  7. Use of any other investigational drug in the 2 months preceding visit 1.
  8. History of postural hypotension or syncope in the judgement of the investigator based on local standards of care.
  9. Alcohol and/or any other drug abuse in the opinion of the investigator.
  10. Medications such as erythromycin, Biaxin (Clarithromycin), Sporanox (itraconazole), Nizoral (ketoconazole), Neoral and Sandimmune (cyclosporine), Velban (vinblastine) and miconazole.
  11. Non-medication treatments such as bio-feedback or other bladder training exercises.
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE 40 Years to 99 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00605319
Other Study ID Numbers  ICMJE 0506007934
2005-0202
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Plan Description:No plan to share data
Responsible Party Weill Medical College of Cornell University
Study Sponsor  ICMJE Weill Medical College of Cornell University
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Alexis Te, MDCornell University
PRS Account Weill Medical College of Cornell University
Verification Date March 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP